Day Lila

Biotech · Monday, 16 November 2026

Written by AI agents built on Claude, from the sources they cite, and overseen by Zeemish. How it's made

This day: every beat The day in 12 minutes

Swipe 12 stories

The FDA turns down ivonescimab, a lung cancer drug invented in China, because it did not help patients live longer

12 stories 18 sources

Signals on this beat

Proof of longer life demanded High ↑
  • The FDA rejected ivonescimab because it did not help patients live longer. [3]
  • The FDA's new draft trial rules say consent forms should name treatments that extend survival. [17]
Outbreaks outrunning the response High ↑
  • In Congo, over 80% of new Ebola cases come from outside the lists of known contacts. [8]
  • In Gaza, lung infections are 33,000 cases higher than at this time last year. [9]
Gentler tests and treatments Building ↑
  • England's health advisers want a swallowed sponge test offered in family doctors' surgeries. [10]
  • Matching womb cancer treatment to the tumour's profile meant mild side effects in 28.3% of women, against 45.2%. [16]
Medicines and kit running short Building →
  • Pfizer will stop selling its menopause drug Premarin in Canada, where its cream has been short since June. [11]
  • The WHO says it struggles to get laboratory supplies into Gaza. [9]

The stories

12 on this beat today.

Each story is told in its parts: what happened, the questions that explain it, how it works, who gains and who pays, and the good news. A part appears when the sources give it.

  1. 01

    The FDA turns down ivonescimab, a lung cancer drug invented in China, because it did not help patients live longer

    1 of 2

    main trial goals met: slower cancer growth, but not longer life

    the trial ran in the US, Canada, Europe and Asia [2]

    7.3% vs 5.0%

    of patients who stopped for side effects, on the drug and on a dummy

    deaths from side effects were 4 on the drug and 5 without it [1]

    What happened

    • The US Food and Drug Administration rejected ivonescimab, a lung cancer drug from Summit Therapeutics and Akeso, Summit said Sunday. [3]
    • Summit wanted it for advanced lung cancer with a faulty EGFR gene, in patients already treated with targeted pills. [1] EGFR is a protein that can drive tumour growth. [4]
    • The FDA's letter said the drug could not be approved because it did not help patients live longer. [3]
    • The New York Times calls the drug a symbol of China's rise in making new medicines. [2]
    • Ivonescimab is one antibody built to grip two targets, PD-1 and VEGF. [1] Summit says both may be more common in tumours than in healthy tissue. [1]
    • The test was HARMONi, a final-stage trial in which neither patients nor doctors knew who got the drug. [1]
    • It ran in the US, Canada, Europe and Asia. [2] Patients got ivonescimab with chemotherapy, or a dummy drug with chemotherapy. [1]
    • The trial had 2 main goals: slowing the cancer's growth, and helping patients live longer. [1]
    • The drug met the first goal and delayed the cancer's worsening. [2] It did not show a statistically significant gain in survival. [2]
    • Side effects made 16 patients, or 7.3%, stop taking ivonescimab. [1] On the dummy drug, 11 patients, or 5.0%, stopped. [1]
    • Side effects killed 4 patients on ivonescimab and 5 on chemotherapy alone, Summit says. [1]
    • Summit argued the trial missed on survival only because patients joined it slowly. [2]
    • It sent the FDA extra analyses of longer follow-up that were not in the trial's original plan. [2] They did not persuade the regulator. [2]
    • Summit says a later look, with more follow-up, showed the same slowing of the cancer in Western patients. [1]
    • STAT, a health news site, says the rejection was not entirely unforeseen. [3]

    Who is involved

    Akeso, a Chinese drugmaker, invented ivonescimab in its own laboratories and sells it in China. [2]

    Summit Therapeutics, a company based in Florida, bought the drug's US rights from Akeso. [2]

    • The FDA said no to the drug
    • Summit and Akeso
    • Summit Therapeutics a Florida drug company that bought the drug's US rights; it asked the FDA for approval
    • The US Food and Drug Administration the US drug regulator; it said no because survival was not shown to improve

    Why it matters

    The ruling lands on patients with this lung cancer who are waiting for more treatment options, Summit says. [1]

    It also hits Akeso, which first developed the drug and sells it in China. [4]

    Ivonescimab is being tested in many more cancers, including colon, bladder and breast tumours. [2]

    Think it through

    1. 1

      Was the drug turned down for being dangerous?

      No: the FDA's reason was the missing survival gain. [3] Deaths from side effects were 4 on the drug and 5 without it. [1]

    2. 2

      Then why isn't slower cancer growth enough?

      Without a survival gain, the FDA said, the data does not support the positive benefit-risk profile in support of approval. [3]

    3. 3

      Is this only about one drug?

      No: on 12 November the FDA hosted a workshop on weighing benefit against harm in ovarian cancer drugs. [6] Its topics included how much survival matters. [6]

    4. 4

      So who loses from the no?

      The no sets back Summit's bid to challenge the standard treatment, Bloomberg says. [4] Akeso, the drug's inventor, takes a blow too. [4]

    5. 5

      Does the drug still have a chance in the US?

      Summit is running trials in lung, colon, bladder and kidney cancers across several regions. [1]

    6. 6

      So who decides if it reaches US patients?

      The FDA decides on approval, and this time it said no because survival did not improve. [3] Summit holds the US rights and the trials still running. [2][1]

    How it works

    Regulators call this a benefit-risk assessment: a drug is approved only when its gains for patients outweigh its costs. [3]

    Ivonescimab's benefit-risk balance needed longer life on the gain side. [3] With only slower growth shown, the FDA judged it did not clearly win. [3]

    Seen it before

    A long bus ride is worth it for a great day out, not for a shop next door.

    The truth

    • What is really going on The FDA turned down ivonescimab because it slowed lung cancer without proving longer life, and its draft trial rules ask that patients be told of drugs that do extend life. [3][17]
    • The rejection rests on one test: the survival gap was not statistically significant, so it could have been chance. [2]
    • Summit's claim that slow enrolment hid a survival gain is its own reading, and it did not persuade the FDA. [2]
    • Nobody knows yet

      Whether ivonescimab can still win US approval in another cancer.

      Summit's trials in colon, bladder and kidney cancers are still running, and Summit names no date for their results. [1]

  1. 02

    Congo's Ebola outbreak still out of control

    What happened

    • Congo's Ebola outbreak, declared on 15 May, is still not under control, Africa's top health agency said on Sunday. [8]
    • More than 11,200 cases and 5,500 deaths have been recorded, government data show. [8]
    • It is caused by the Bundibugyo strain, which kills about 1 in 2 people it infects. [8] No vaccine or medicine has been made specifically for it. [8]
    • The virus has reached 8 of Congo's 26 provinces, mostly in the conflict-torn east. [7]
    • Children made up 35% of deaths recorded up to 4 November, according to UNICEF, the UN children's agency. [7]

    How it unfolded

    1. This month vaccine trials approved
    2. Early 2027 results expected

    Why it matters

    Health workers have struck over pay that is months late, sometimes leaving sick patients untreated. [7]

    Cases have now been found in East, Central and West Africa, the widest spread of any Ebola outbreak there. [8]

    Think it through

    1. 1

      Why can't health teams catch up?

      Over 80% of new cases come from people nobody was watching, Africa CDC's head Jean Kaseya says. [8]

      80 of 100

      new cases from outside contact lists

    2. 2

      Is the promised money arriving?

      Only $1.3bn of the $2.9bn donors pledged has been released, Kaseya says. [8]

      money promised against money paid
    3. 3

      So who can turn it around?

      Donors hold most of the pledged money. [8] Congo's government holds the payroll that unpaid health workers are waiting on. [8]

    How it works

    Epidemiologists call it contact tracing: finding everyone a sick person met, and watching them until the danger passes.

    Most new Ebola cases in Congo are on no contact list, so tracing is not keeping up. [8]

    Seen it before

    A teacher who checks only the names on the register misses the pupils who wandered in.

    The truth

    • What is really going on In Congo and Gaza the gap is reaching people: most new Ebola cases are on no contact list, and the WHO struggles to bring lab supplies into Gaza. [8][9]
    • The Hindu's report says the outbreak is on track to pass West Africa's toll. [7] Africa CDC still ranks it second-deadliest on record. [8]

    Good news

    • At least 3,000 people have recovered from Ebola in Congo and gone home, the WHO said. [8]

    What comes next

    The WHO expects results from trials of 2 new Ebola vaccines in early 2027. [8]

  2. 03

    Lung infections surge in flooded Gaza

    What happened

    • The World Health Organization warned on Friday of surging infections of the airways and lungs in Gaza. [9] Heavy rain flooded tens of thousands of tents. [9]
    • These infections are 33,000 cases higher than at this time last year, WHO's Reinhilde Van De Weerdt said. [9]
    • They make up 11% of all visits to doctors in Gaza. [9]
    • Nearly 1,000,000 displaced people live in places at risk of flooding, and 400,000 are at extremely high risk. [9]

    Why it matters

    Damp brings mould and bacteria that drive lung infections, especially in young children, the WHO said. [9]

    Think it through

    1. 1

      Why does crowding make it worse?

      People squeezed into smaller spaces pass a virus between each other more easily, Van De Weerdt said. [9]

    2. 2

      What is missing to treat people?

      Most medicines are getting in, but laboratory supplies to diagnose patients are hard to bring in, the WHO says. [9]

    3. 3

      So who decides what kit gets in?

      COGAT, the Israeli military agency that coordinates aid, says rebuilding equipment enters only once Hamas disarms. [9] It says no medicine request was refused. [9]

    How it works

    Epidemiologists call it the contact rate: how often people come close enough to pass on a germ.

    As Gaza's people are pushed into less space, the contact rate rises and infections spread faster, the WHO says. [9]

    Seen it before

    A cold spreads faster in a packed classroom than in an empty hall.

    The truth

    • The report links the crowding to Israel's army advancing the ceasefire's Yellow Line. [9] The army says the line protects Israelis and is not meant to harm civilians. [9]
    • Nobody knows yet

      How many people in Gaza will fall ill this winter.

      Winter has not fully set in, and the WHO expects cold, floods and crowded shelters to push cases higher. [9]

  1. 04

    England may offer a swallowed sponge test

    What happened

    • NICE, which advises England's health service, wants sponge tests offered to some people with bad, lasting indigestion. [10] The draft guidelines aim to spot food-pipe cancer. [10]
    • A patient swallows a dissolving capsule on a thread, which releases a tiny sponge in the stomach. [10] The sponge collects cells as it is pulled out. [10]
    • The test takes minutes in a family doctor's surgery and is gentler than an endoscopy, a camera check in hospital. [10]
    • Between 1 and 2 adults in every 100 have Barrett's oesophagus, a food-pipe change that raises cancer risk. [10]

    How it unfolded

    1. Now draft guidelines
    2. New year final decision

    Why it matters

    Demand for endoscopy is high, so some people with Barrett's oesophagus are not checked as often as advised. [10]

    Think it through

    1. 1

      Does a clear result mean no cancer?

      No: NICE says no test catches every case, so people with a clear result should still be watched. [10]

    2. 2

      So who gains most?

      The health service needs fewer camera checks and frees up resources, says Peter Johnson, NHS England's cancer director. [10]

    How it works

    Doctors call this triage: a quick, cheap test sorts out who needs the bigger one.

    The sponge test picks out people with worrying changes for more tests, says NICE's chief Jonathan Benger. [10]

    Seen it before

    A school nurse takes temperatures first and sends only the feverish pupils home.

    Why the same side effects can be accepted for one drug and refused for another

    Regulators weigh what a medicine gives patients against what it costs them, so a harm is judged only beside the gain it buys.

    The twist

    A side effect is never acceptable or unacceptable on its own: it is judged by how much the medicine gives back.

    The picture

    In PORTEC-4a, matching treatment to the tumour's risk cut mild side effects while severe ones stayed rare. Less treatment where the gain is small means less harm.

    Step by step

    1. A medicine brings a gain and a harm
    2. The regulator sets the two side by side
    3. A big proven gain can carry real harm
    4. A small or unproven gain cannot
    5. So the same harm means yes for one drug, no for another

    The same force, elsewhere today

    Where this chain is also running, in today's other stories.

    • Matching womb cancer care

      Where the tumour's profile showed low risk, doctors gave less radiation, and 28.3% had mild side effects against 45.2%.

    • The narcolepsy pill reaching US patients

      The DEA weighed Orzeyful's misuse risk as low and put it in Schedule IV, so its medical use could go ahead.

    • The FDA's draft rules for first cancer trials

      Patients must be told by name of treatments that extend life, so they can weigh a trial drug against them.

    • England's sponge test

      A gentler test is traded against a camera check that sees more, so NICE says a clear result still needs watching.

    Seen it before

    Speed limits

    A higher limit saves drivers time and costs lives, so it is set where the trade is judged fair.

    Food preservatives

    A chemical with a small risk is allowed because spoiled food would harm more people.

    Airport security

    Each extra check costs passengers time, so it stays only if it stops enough danger.

    The catch

    The scale needs a gain that has been proven; a real gain that a trial could not show still weighs nothing.

    And the whole of it

    Patients waiting for a drug, the company that made it and the reviewers who said no each stand at a different end of this scale. Anyone who has taken a medicine has already been weighed on it.

    The truth

    • NICE says no test catches every case. [10] How many the sponge misses decides how far it can replace the camera. [10]

    Good news

    • Thousands of people have already been helped by the test in NHS pilots, Johnson says. [10]

    What comes next

    NICE will make its final recommendations in the new year. [10]

  1. 05

    FDA drafts rules for first cancer trials

    What happened

    • The FDA has issued draft guidance for the first trials of new drugs for solid tumours, not blood cancers. [17]
    • Its aim is to protect the safety and rights of the people in those trials. [17]
    • Trials should generally not set an upper age limit, the draft says. [17]
    • It encourages including children with incurable solid tumours once adult data suggest the drug works. [17] Teenagers may join alongside adults after early adult data. [17]
    • The guidance is not binding, and the public has 60 days to comment once its notice is published. [17]

    Who is involved

    • Older patients no upper age limit

    Why it matters

    It lands on cancer patients looking for a trial, especially older people and children with no cure left. [17]

    Think it through

    1. 1

      Why would strict entry rules be a problem?

      Too-strict rules slow recruitment and make results fit fewer of the drug's future patients, the FDA says. [17]

    2. 2

      What must a patient be told first?

      The consent form should name the treatments already shown to make patients live longer. [17]

    3. 3

      So who has the final say?

      Drug companies can still set their own rules, because the draft only recommends. [17] The FDA reviews each trial plan before it starts. [17]

    How it works

    Research ethicists call it informed consent: a person joins a trial only after hearing its risks, benefits and other options.

    The FDA's draft makes informed consent sharper: patients should hear, by name, of treatments that extend survival. [17]

    Seen it before

    Before a school trip, parents sign a form only after reading where it goes and what could go wrong.

    The idea, in story 04: Why the same side effects can be accepted for one drug and refused for another →

    The truth

    • It is a draft, so its final wording, and whether companies follow it, are still open. [17]
  2. 06

    Matching womb cancer care cuts side effects

    What happened

    • A trial called PORTEC-4a gave women with early womb-lining cancer treatment chosen by their tumour's molecular profile. [16]
    • Of 564 women, 367 got the profile-based plan and 197 got the standard internal radiation, vaginal brachytherapy. [16]
    • In the profile group, doctors chose no treatment, internal radiation or wider pelvic radiation, depending on the tumour. [16]
    • The new paper, in the British Journal of Cancer, reports side effects and quality of life. [16] Half the women were followed for over 58 months. [16]

    Why it matters

    It matters for women whose tumour profile shows lower risk, as some were given no extra treatment at all. [16]

    Think it through

    1. 1

      Did lighter treatment mean fewer side effects?

      Yes: at the end of treatment, 28.3% had mild to moderate side effects, against 45.2% on standard radiation. [16]

      side effects at the end of treatment
    2. 2

      What still weighs on these women?

      Sexual activity was lower than normal in both groups, mostly for personal reasons rather than the illness. [16]

    How it works

    Cancer doctors call it risk-adapted treatment: each patient gets as much treatment as their tumour's risk calls for.

    In PORTEC-4a, the tumour's profile set each woman's treatment, and severe side effects stayed rare, at 1% against 2%. [16]

    Seen it before

    A coat chosen by the day's weather keeps you warm without making you sweat on a mild day.

    The idea, in story 04: Why the same side effects can be accepted for one drug and refused for another →

    The truth

    • This paper covers side effects and quality of life. [16] That the cancer stays away just as well rests on the trial's earlier result. [16]

    Good news

    • Women with early womb-lining cancer whose treatment matched their tumour had fewer side effects: 28.3% had mild ones, against 45.2% on standard radiation.
  3. 07

    A narcolepsy pill reaches US patients

    What happened

    • The drugmaker Takeda says its narcolepsy pill Orzeyful is now on sale in the US. [11] Narcolepsy is a rare sleep disorder. [11]
    • It is the first treatment aimed at the disorder's underlying cause, Takeda says. [11]
    • The last hurdle was a decision by the US Drug Enforcement Administration, the DEA. [11]
    • The list price is $16,500 for a bottle of 60 tablets, at every strength. [11]

    Why it matters

    About 120,000 people in the US have narcolepsy. [11]

    Think it through

    1. 1

      Why did a drug police agency get a say?

      The DEA ranks drugs by how likely they are to be misused. [11] Orzeyful could not be sold until it was ranked. [11]

    2. 2

      So how risky does the DEA think it is?

      It put Orzeyful in Schedule IV, the class for drugs with a low chance of misuse and dependence. [11]

    How it works

    Drug law calls it scheduling: sorting medicines into classes by how likely people are to misuse them.

    The DEA scheduled Orzeyful as a low-risk Schedule IV drug, which let Takeda start selling it. [11]

    Seen it before

    A school lets pupils carry a water bottle but keeps the science lab chemicals locked up.

    The idea, in story 04: Why the same side effects can be accepted for one drug and refused for another →

    The truth

    • The report gives no trial figures, so how much Orzeyful helps against its $16,500 price is not shown here. [11]
  4. 08

    Pfizer stops selling Premarin in Canada

    What happened

    • Pfizer will stop selling Premarin, its hormone replacement therapy, in Canada after an internal review. [11]
    • Hormone replacement therapy eases the symptoms of menopause. [11] Premarin came as a vaginal cream and 3 strengths of tablets. [11]
    • The cream has been short in Canada since June, and no more batches will be sent. [11]

    How it unfolded

    1. June the cream runs short
    2. Now no more batches

    Why it matters

    Other menopause hormone products in Canada also face supply limits. [11]

    Think it through

    1. 1

      Why is demand rising?

      US prescriptions rose after the FDA removed long-standing safety warnings on these drugs a year ago. [11]

    2. 2

      So who decides what Canadian women can get?

      Pfizer decides which markets it supplies, and it has chosen to leave this one. [11]

    How it works

    Economists call it a shortage: more people want a product than its makers supply.

    Premarin's shortage in Canada ends with no supply at all, as Pfizer sends no more batches. [11]

    Seen it before

    When the shop's favourite cereal runs out for months, it may simply stop stocking it.

    The truth

    • Pfizer named only an internal review, so whether cost, factories or demand drove the exit is not known. [11]
    • Nobody knows yet

      Whether women in Canada will find another menopause hormone treatment.

  5. 09

    Nvidia's turmoil reaches drug research

    What happened

    • Jensen Huang resigned as chief of Nvidia, a maker of AI computing technology, amid reported affairs. [14]
    • Nvidia's AI powers many partnerships with drugmakers and lab-equipment firms, going back at least 5 years. [14]
    • In January, Nvidia and Eli Lilly committed $1 billion over 5 years to a joint AI lab for drug discovery. [14]

    Who is involved

    The New York Times reported, from 5 unnamed sources, an affair with Kimberly Powell, Nvidia's head of health care. [14]

    • Kimberly Powell ran Nvidia's health and life sciences work

    Why it matters

    Lilly, AstraZeneca and GSK had not said by deadline whether they would review their Nvidia partnerships. [14]

    Think it through

    1. 1

      Who loses most if Nvidia pulls back?

      AI drug-discovery startups that raise money from Nvidia, says Alex Zhavoronkov of Insilico Medicine. [14] Nvidia joined 122 startup funding deals this year. [14]

      122startup deals Nvidia joined this year

    2. 2

      So do the partners stay?

      Of Nvidia, 10x Genomics' chief Serge Saxonov said it's not just one person who made it so. [14] The big drugmakers have not said either way. [14]

    How it works

    Business scholars call it key-person risk: when a firm leans on one leader, losing him shakes everyone tied to it.

    A Bernstein analyst doubts any new chief can fill Huang's shoes, which is key-person risk for Nvidia's drug partners. [14]

    Seen it before

    A team built around one star player struggles when he leaves mid-season.

    The truth

    • The affairs are reported from unnamed sources. [14] No drug partner has said it will change anything, which decides whether drug research feels this at all. [14]
    • Nobody knows yet

      Whether Jensen Huang leaving Nvidia changes any of its drug research partnerships.

  6. 10

    Apple tests an AI health chat app

    What happened

    • Apple and OpenEvidence, an AI tool that doctors use, launched a study of an experimental health chat app on Sunday. [13]
    • They announced it on stage at HLTH, a health conference in Las Vegas. [13]

    Who is involved

    Sumbul Desai, Apple's vice president of health and fitness, announced the study. [13]

    • Apple runs the study
    • OpenEvidence the medical partner
    • Sumbul Desai Apple's health chief

    Why it matters

    The study could point both companies in new directions, STAT reports. [13]

    Think it through

    1. 1

      Why run it as a study, not a product?

      "We're studying what builds user trust," Desai said. [13] She said it also checks how people understand the answers. [13]

    2. 2

      So why pick OpenEvidence?

      Desai says Apple wanted a partner grounded in medicine, and that is OpenEvidence. [13]

    How it works

    Researchers call this a usability study: watching how real people use a tool before it goes on sale.

    Here Apple wants to understand how people use health chatbots, through an experimental app. [13]

    Seen it before

    A game is played by testers for weeks before players can buy it.

    The truth

    • Apple calls it a study, so the quality of the app's answers is still being measured. [13]
  7. 11

    Why sour quiets sweet, in mice

    What happened

    • Stephen Roper's team at the University of Miami found that sour tastes make taste-bud cells release serotonin, in mice. [15]
    • Serotonin is a chemical messenger between cells. [15] Here it damps nearby cells that sense sweet and bitter. [15]
    • Sour signals then travel to the brain along the pathway for tastes we dislike. [15] The study is in the Journal of Neuroscience. [15]

    Why it matters

    It shows taste buds change signals before they reach the brain, rather than just passing them on. [15]

    Think it through

    1. 1

      Is that why cooks add lemon?

      This has been known by chefs for ages, Roper says. [15] His team worked out how it happens inside the taste bud. [15]

    2. 2

      So is sour even a real taste?

      Neuroscientist Emily Liman says that is still debated. [15] Sour cells might be reacting to something else, like ammonium from decay. [15]

    How it works

    Neuroscientists call it lateral inhibition: one sensing cell quiets the cells beside it.

    In these mice, sour-sensing cells use serotonin to quiet nearby sweet and bitter cells, the lateral inhibition at work. [15]

    Seen it before

    One loud voice in a classroom makes it hard to hear the quiet ones.

    The truth

    • The work was done in mice, not people, and how the two taste pathways interact is still unclear, Roper says. [15]
  8. 12

    Australia's medical council backs puberty blockers, with conditions

    What happened

    • Australia's National Health and Medical Research Council, its largest medical research body, issued interim advice on Monday. [18]
    • It says puberty blockers are appropriate for some transgender children, in certain circumstances. [18] It came after a year-long review of international evidence. [18]
    • Puberty blockers are drugs that stop the body producing oestrogen and testosterone. [18]
    • The council rejected a 'wait and see' approach, calling it a form of withholding care. [18]

    How it unfolded

    They have treated children with very early puberty since the 1970s, and been used in gender care since the 1990s. [18]

    The national government asked for the advice after Queensland and the Northern Territory banned the drugs in public hospitals. [18]

    1. 1970s used for very early puberty
    2. 1990s used in gender care
    3. 18 January comments close
    4. 2028 full guidelines

    Why it matters

    The advice could put pressure on state and territory governments to reconsider their positions. [18]

    Think it through

    1. 1

      Why does this council's word carry weight?

      It is an independent agency funded by the national government, and this is national clinical advice. [18]

    2. 2

      Is it a big change for doctors?

      No: it largely matches AusPATH's standards, until now Australia's only guidelines for doctors on this care. [18]

    3. 3

      So who decides if children get them?

      State and territory governments run their public hospitals and set the bans. [18] The council's advice adds pressure on them. [18]

    How it works

    Doctors call this a clinical practice guideline: advice built on a systematic review of every good study.

    The council's committee wrote its puberty blocker advice on a systematic review of the evidence, the council says. [18]

    Seen it before

    Before choosing a phone, a careful buyer reads every review, not only the first one.

    The truth

    • The advice rests on the council's evidence review. [18] New Zealand's government brought in a ban despite wide opposition in its health sector. [18]

    What comes next

    Public comments are open until 18 January, and the full guidelines are expected in 2028. [18]

Across the beats